In yet another attempt to curb coronavirus infection, Hyderabad-based Biological E has claimed its covid19 vaccine to be 90 percent effective. The company’s made-in-India vaccine is
likely to be a gamechanger in the battle against coronavirus pandemic.
A few weeks ago the government placed an order of 300 million doses of Biological E’s corona vaccine, which could be called Corbevax. NK Arora, the chairperson of the Center’s Covid Working Group said that the vaccine has entered the Phase 3 trials and might be available by October.
The Biological E’s Corbevax is similar to the Novavax vaccine, which is more than 90 per cent effective on Covid variants as well, said Dr Arora. Meanwhile, Novavax is to be produced in India by the Serum Institute of India, which also makes Covishield by Oxford-AstraZeneca.
Also Read: ‘Covaxin contains calf serum’: Congress leaders link Covid19 vaccine to cow slaughter
Dr Arora said, “Novavax, in the past week has created a rage because India is going to manufacture almost a billion doses a year. It is going to be a simple and cheaper vaccine with more than 90 percent effectiveness.
He further added, “a very similar Indian vaccine is also under phase 3 trial, which is the Bio E vaccine. These vaccines are safe across the age groups and have very high effectiveness.”
Bio E vaccine, in particular, holds a lot of potentials as the vaccine may be offered for just $3.4 which is Rs. 250 for two doses.
“Bio E is most likely to be out in October with an efficacy similar to Novavax. In other words, 90 percent. They are moving to stage 3 trials soon,” said Dr. Arora.
Meanwhile, he also referred to Zydus- Cadila's product and India’s own mRNA-based vaccine which will be manufactured by Pune-based Gennova Biopharmaceuticals. Showing confidence in vaccine development, Dr. Arora said that “there is a strong chance that the world will ultimately depend on India for affordable and effective vaccines against coronavirus infection.”